Cost Analysis Comparing an Anthracycline/Docetaxel Regimen to CMF in Patients with Early Stage Breast Cancer

Publisher： Karger

E-ISSN： 2296-5262|32|8-9|473-481

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.32, Iss.8-9, 2009-07, pp. : 473-481

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Docetaxel in Patients with Anthracycline-Resistant Advanced Breast Cancer

By  

Oncology, Vol. 60, Iss. 1, 2000-12 ,pp. : 60-65

Karger

Access to resources Recommend Favorite

Incidence and Predictors of Febrile Neutropenia among Early-Stage Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy in Korea

By  

Oncology, Vol. 91, Iss. 5, 2016-09 ,pp. : 274-282

Karger

Access to resources Recommend Favorite

A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52)

By  

CANCER, Vol. 121, Iss. 20, 2015-10 ,pp. : 3639-3648

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy of the CMFVP Regimen in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane

By  

Oncology Research and Treatment, Vol. 35, Iss. 1-2, 2012-01 ,pp. : 24-26

Karger

Access to resources Recommend Favorite

Randomised Trial: One Cycle of Anthracycline-Containing Adjuvant Chemotherapy Compared with Six Cycles of CMF Treatment in Node-Positive, Hormone Receptor-Negative Breast Cancer Patients

By  

Oncology Research and Treatment, Vol. 26, Iss. 2, 2003-05 ,pp. : 115-119

Karger

Access to resources Recommend Favorite